Richard Carvajal is an Oncology physician affiliated with Northwell Health. OpenAlex indexes 725 publications with 39,493 citations (h-index 74); ClinicalTrials.gov lists 5 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
177 Fort Washington Ave
New York, NY 100323733
Telephone
212-305-6514Registry record last updated 13 Jun 2016.
Clinical trials
- Adjuvant Tebentafusp in High Risk Ocular Melanoma
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
Sponsor: Columbia University
- Epacadostat and Pembrolizumab in Patients With GIST
Sponsor: Columbia University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- HISTOSONICS, INC.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2008–2021 per NIH RePORTER. The latest:
- Exploratory clinical trial of topical Imiquimod 5% cream as window-of-opportunity monotherapy for early-stage oral cancer
Columbia University Health Sciences
FY2021$126,755R21CA252441 - Randomized Phase II Study of QS-DG +/- Trivalent Ganglioside Vaccine in Stage IV
Sloan-Kettering Inst Can Research
FY2009$426,600R21CA133866 - Randomized Phase II Study of QS-DG +/- Trivalent Ganglioside Vaccine in Stage IV
Sloan-Kettering Inst Can Research
FY2008$426,881R21CA133866
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
New England Journal of Medicine
2023 - Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Journal of Clinical Oncology
2023 - Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
Journal for ImmunoTherapy of Cancer
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Alexander Iribarne, MD
Northwell Health
Andrew Krumerman, MD
Northwell Health
Shoko Mori, MD
Northwell Health
Elana Koss, MD
Northwell Health
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”